Challenges and Recent Advances in Medulloblastoma Therapy

Publication date: Available online 20 October 2017 Source:Trends in Pharmacological Sciences Author(s): Vinod Kumar, Virender Kumar, Timothy McGuire, Donald W. Coulter, John G. Sharp, Ram I. Mahato Medulloblastoma (MB) is the most common childhood brain tumor, which occurs in the posterior fossa. MB tumors are highly heterogeneous and have diverse genetic make-ups, with differential microRNA (miRNA) expression profiles and variable prognoses. MB can be classified into four subgroups, each with different origins, pathogenesis, and potential therapeutic targets. miRNA and small-molecule targeted therapies have emerged as a potential new therapeutic paradigm in MB treatment. However, the development of chemoresistance due to surviving cancer stem cells and dysregulation of miRNAs remains a challenge. Combination therapies using multiple drugs and miRNAs could be effective approaches. In this review we discuss various MB subtypes, barriers, and novel therapeutic options which may be less toxic than current standard treatments.
Source: Trends in Pharmacological Sciences - Category: Drugs & Pharmacology Source Type: research